MDM2 and cancer: These results from genetically engineered mouse models, together with other results from cell cultures, have demonstrated that while MDM2 can effectively degrade mutp53 in cultured normal and cancer cells as well as normal mouse tissues, tumors develop specific mechanisms to impair MDM2-mediated mutp53 degradation, leading to mutp53 accumulation in tumors (7, 24–26, 59).